Clinical trial NCT00423644: A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b
Official title: A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Multiple Myeloma
Keywords: Multiple Myeloma
arsenic
cancer study
failed treatment
Lead sponsor: Alaunos Therapeutics
Sponsor class: INDUSTRY
First posted: 2007-01-18
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma


Eligibility criteria: Inclusion Criteria

1. Subjects with a confirmed diagnosis of active multiple myeloma with measurable protein criteria present to evaluate response. Measurable disease is defined as having at least one of the following criteria within 28 days prior to registration:

   1. Serum M-protein level \> 0.5 gm/dl (10.0 g/L) measured by serum protein electrophoresis.
   2. Urinary M-protein excretion \> 0.2 g/24 hours by urine electrophoresis.
2. Subjects must have relapsed or resistant disease, defined as either relapsing or is resistant after \> 2 lines of prior therapy for myeloma. A minimum of 42 days must have elapsed since prior autologous or allogeneic transplant;
3. Informed consent compliant with ZIOPHARM policies and approved by the Human Investigation Review Committee with jurisdiction over the site;
4. ECOG performance score ≤ 1;
5. No chemotherapy, bortezomib, lenalidomide, thalidomide, arsenic trioxide, radiation therapy or immune therapy for ≥ 3 w and recovered from all treatment associated toxicities prior to registration; 5a. Patients may not receive more than the equivalent of 10 mg of prednisone per day for 2 weeks prior to registration.
6. Age ≥ 18;
7. Granulocytes ≥ 1.0 x 109/L; platelets ≥ 50 x 109/L;
8. Bilirubin ≤ 2.0 mg/dL; AST and ALT ≤ 2 x ULN;
9. Creatinine ≤ 3 X ULN.
10. No investigational agents within 28 days of study entry.
11. Males who agree to use a double-barrier method of birth control, (Double barrier method is defined as: a condom and either a diaphragm/cervical cap or an IUD).

Exclusion Criteria

1. NYHA functional class ≥ 3, myocardial infarction ≤ 6 mo or uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation; QTc ≥ 450msec; AV-block ≥ grade-2 or LBBB;
2. Women of childbearing potential. (Non-childbearing potential is defined as: surgical sterilization or 2 years post-menopausal)
3. Active infection requiring antibiotics;
4. Allergy to ZIO-101 or its excipients;
5. Baseline confusion or dementia, defined as grade \> 2 CTCAE Version 3.0;
6. Significant neurotoxicityneuropathology, defined as grade \> 2 neurotoxicity neuropathology per CTCAE Version 3.0;
7. Prior seizures ≥ grade-3 in CTC v.3 criteria.
8. Prior history of neurological deficits (e.g., stroke, dementia, ischemia) that has the potential to confound a post-dose neurological assessment

Primary outcomes:
measure: Response Rate
timeFrame: 6 months
Secondary outcomes:
measure: Survival (overall and progression free)
timeFrame: 6 months
measure: toxicities
timeFrame: 6 months
Other outcomes:
Locations:
city: Glendale
country: United States
state: Arizona
city: Santa Barbara
country: United States
state: California
city: Santa Rosa
country: United States
state: California
city: West Hollywood
country: United States
state: California
city: Bethesda
country: United States
state: Maryland
city: Buffalo
country: United States
state: New York
city: Charlotte
country: United States
state: North Carolina
city: Sioux Falls
country: United States
state: South Dakota
Study officials:
References: